What is Valneva?
Founded in 2012 and headquartered in France, Valneva is a specialized biotechnology firm dedicated to the research, development, and manufacturing of vaccines for infectious diseases. The company operates at the intersection of scientific innovation and commercial production, maintaining a significant footprint across Europe, including facilities in Sweden and the United Kingdom. Valneva's market position is defined by its focus on preventative medicine, addressing critical public health challenges through a combination of proprietary research and strategic manufacturing partnerships. As a publicly traded entity, the company bridges the gap between early-stage clinical development and large-scale vaccine distribution, making it a vital component of the international healthcare infrastructure.
How much funding has Valneva raised?
Valneva has raised a total of $749.8M across 5 funding rounds:
Debt
$27.6M
Debt
$100M
Grant
$27.2M
Corporate Investment
$95M
Debt
$500M
Debt (2016): $27.6M with participation from European Investment Bank
Debt (2020): $100M led by Orbimed and Deerfield
Grant (2022): $27.2M, investors not publicly disclosed
Corporate Investment (2022): $95M featuring Pfizer
Debt (2025): $500M, investors not publicly disclosed
Key Investors in Valneva
Pfizer
Pfizer is a global biopharmaceutical leader that researches, develops, and manufactures medicines and vaccines across diverse therapeutic areas including oncology and immunology.
European Investment Bank
The European Investment Bank is the nonprofit lending institution of the European Union, providing long-term financing for projects that support EU policy objectives.
Deerfield
Deerfield Management is a healthcare-focused investment firm that supports innovation through flexible capital models, data-driven research, and strategic partnerships.
What's next for Valneva?
With the recent influx of capital, Valneva is well-positioned to accelerate its clinical development programs and expand its manufacturing capacity. The strategic focus will likely center on scaling production for its existing vaccine portfolio while simultaneously advancing its pipeline of novel candidates targeting emerging infectious threats. By utilizing this latest financing, the company aims to strengthen its competitive advantage in the pharmaceutical sector, potentially exploring new therapeutic areas or enhancing its technological platforms. Investors and industry analysts will be closely monitoring how Valneva deploys these resources to achieve key regulatory milestones and expand its global market reach, ultimately aiming to deliver sustainable value to shareholders while addressing urgent global health needs.
See full Valneva company page
